Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Serum Heavy Light Chain Immunoassays Compared To Traditional Serum Based Laboratory Testing For The Diagnosis and Screening Of Monoclonal Gammopathies

Qingli Wu, PhD, Deborah J. Kuhn, Ph.D.

Blood (2013) 122 (21): 5345.

https://doi.org/10.1182/blood.V122.21.5345.5345

Published: 2013

Journal Articles

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones, Richard Woessner, Chad C. Bjorklund, Wencai Ma, R. Eric Davis, Pei Lin, Hua Wang, Timothy L. Madden, Caimiao Wei, Veerabhadran Baladandayuthapani, Michael Wang, Sheeba K. Thomas, Jatin J. Shah, Donna M. Weber, Robert Z. Orlowski

Blood (2012) 120 (16): 3260–3270.

https://doi.org/10.1182/blood-2011-10-386789

Published: 2012

Includes: Supplemental data

Journal Articles

Blockade of IGF-1R with OSI-906 Overcomes Bortezomib-Resistance in Multiple Myeloma

Deborah J. Kuhn, Ph.D., Hua Wang, Ph.D., Richard Julian Jones, PhD, Chad C. Bjorklund, Ph.D., Robert Z. Orlowski, MD, PhD

Blood (2011) 118 (21): 925.

https://doi.org/10.1182/blood.V118.21.925.925

Published: 2011

Journal Articles

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Chad C. Bjorklund, Ph.D., Sharon Lea Aukerman, PhD, Antonia Lopez-Girona, Ph.D., Mohamad Hussein, MD, Rajesh Chopra, PhD, Isere Kuiatse, Ph.D., Deborah J. Kuhn, Ph.D., Caimiao Wei, PhD, Robert Z. Orlowski, MD, PhD

Blood (2011) 118 (21): 928.

https://doi.org/10.1182/blood.V118.21.928.928

Published: 2011

Journal Articles

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis.

Deborah J. Kuhn, Ph.D., Chad C. Bjorklund, Ph.D., Valeria Magarotto, M.D., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 2739.

https://doi.org/10.1182/blood.V114.22.2739.2739

Published: 2009

Journal Articles

Activation of the Wnt/β-Catenin Pathway Mediates Lenalidomide Resistance in Multiple Myeloma.

Chad C. Bjorklund, Ph.D., Deborah J. Kuhn, Ph.D., B.Sc., Jairo A. Matthews, B.A., Michael Wang, M.D., Veerabhadran Baladandayuthapani, Ph.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 113.

https://doi.org/10.1182/blood.V114.22.113.113

Published: 2009

Journal Articles

Bortezomib and EGCG: no green tea for you?

Jatin J. Shah, Deborah J. Kuhn, Robert Z. Orlowski

Blood (2009) 113 (23): 5695–5696.

https://doi.org/10.1182/blood-2009-03-204776

Published: 2009

Journal Articles

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

Deborah J. Kuhn, Sally A. Hunsucker, Qing Chen, Peter M. Voorhees, Marian Orlowski, Robert Z. Orlowski

Blood (2009) 113 (19): 4667–4676.

https://doi.org/10.1182/blood-2008-07-171637

Published: 2009

Includes: Supplemental data

Journal Articles

Targeting the p27 E3 ligase SCF Skp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy

Qing Chen, Weilin Xie, Deborah J. Kuhn, Peter M. Voorhees, Antonia Lopez-Girona, Derek Mendy, Laura G. Corral, Veronique Plantevin Krenitsky, Weiming Xu, Laure Moutouh-de Parseval, David R. Webb, Frank Mercurio, Keiichi I. Nakayama, Keiko Nakayama, Robert Z. Orlowski

Blood (2008) 111 (9): 4690–4699.

https://doi.org/10.1182/blood-2007-09-112904

Published: 2008

Includes: Supplemental data

Journal Articles

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fijs W. B. van Leeuwen, Asher A. Chanan-Khan, Robert Z. Orlowski

Blood (2007) 110 (9): 3281–3290.

https://doi.org/10.1182/blood-2007-01-065888

Published: 2007

Includes: Supplemental data

Journal Articles

Targeting the p27 Kip1 E3 Ubiquitin Ligase for the Treatment of Multiple Myeloma and Other Hematological Malignancies.

Qing Chen, PhD, Weilin Xie, PhD, Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, Derek Mendy, MD, Antonia Lopez-Girona, PhD, Veronique Plantevin, PhD, Weiming Xu, PhD, Laura De Parseval, PhD, Laura G. Corral, PhD, Emilia Glezer, PhD, Kyle Chan, PhD, Frank Mercurio, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 372.

https://doi.org/10.1182/blood.V108.11.372.372

Published: 2006

Journal Articles

Enhancing Activity of Bortezomib Against Multiple Myeloma (MM) through Inhibition of Interleukin (IL)-6 Signaling: A Role for Repression of Myeloid Cell Leukemia (Mcl)-1.

Peter M. Voorhees, George W. Small, Deborah J. Kuhn, Qing Chen, Sally A. Hunsucker, Robert Corringham, Carlos A. Garay, Mohamed H. Zaki, Jeffrey Nemeth, Robert Z. Orlowski

Blood (2006) 108 (11): 3414.

https://doi.org/10.1182/blood.V108.11.3414.3414

Published: 2006

Journal Articles

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, Qing Chen, PhD, John S. Strader, Frank Bruzzese, PhD, Jeffrey P. Ciavarri, PhD, Zhigen Hu, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3458.

https://doi.org/10.1182/blood.V108.11.3458.3458

Published: 2006

Journal Articles

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Deborah J. Kuhn, PhD, Qing Chen, PhD, Peter M. Voorhees, MD, John S. Strader, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Fred W. van Leeuwen, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3461.

https://doi.org/10.1182/blood.V108.11.3461.3461

Published: 2006

Journal Articles

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

Qing Chen, PhD, Vishwan Pamarthi, Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3425.

https://doi.org/10.1182/blood.V108.11.3425.3425

Published: 2006

Journal Articles

CNTO328 Abrogates Glucocorticoid (GC) Resistance Conferred by Interleukin (IL)-6 and the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Peter M. Voorhees, George W. Small, Deborah J. Kuhn, Qing Chen, Sally A. Hunsucker, Robert Corringham, Carlos A. Garay, Mohamed H. Zaki, Jeffrey Nemeth, Robert Z. Orlowski

Blood (2006) 108 (11): 3473.

https://doi.org/10.1182/blood.V108.11.3473.3473

Published: 2006

Journal Articles

Identification of Novel Inhibitors That Specifically Target the Immunoproteasome, and Selectively Induce Apoptosis in Multiple Myeloma and Other Immunoproteasome-Expressing Model Systems.

Robert Z. Orlowski, MD, PhD, Deborah J. Kuhn, PhD, George W. Small, PhD, Charlene Michaud, BA, Marian Orlowski, MD

Blood (2005) 106 (11): 248.

https://doi.org/10.1182/blood.V106.11.248.248

Published: 2005

Journal Articles

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Peter M. Voorhees, MD, Deborah J. Kuhn, PhD, George W. Small, PhD, John S. Strader, PA, Robert Corringham, MD, Mohamed H. Zaki, MD, PhD, Jeffrey Nemeth, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1574.

https://doi.org/10.1182/blood.V106.11.1574.1574

Published: 2005

Journal Articles

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, PA, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1576.

https://doi.org/10.1182/blood.V106.11.1576.1576

Published: 2005

NARROW

Serum Heavy Light Chain Immunoassays Compared To Traditional Serum Based Laboratory Testing For The Diagnosis and Screening Of Monoclonal Gammopathies

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Blockade of IGF-1R with OSI-906 Overcomes Bortezomib-Resistance in Multiple Myeloma

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Bortezomib Resistance Is Mediated by Increased Signaling through the Insulin-Like Growth Factor-1/Akt Axis.

Activation of the Wnt/β-Catenin Pathway Mediates Lenalidomide Resistance in Multiple Myeloma.

Bortezomib and EGCG: no green tea for you?

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

Targeting the p27 E3 ligase SCF Skp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Targeting the p27 Kip1 E3 Ubiquitin Ligase for the Treatment of Multiple Myeloma and Other Hematological Malignancies.

Enhancing Activity of Bortezomib Against Multiple Myeloma (MM) through Inhibition of Interleukin (IL)-6 Signaling: A Role for Repression of Myeloid Cell Leukemia (Mcl)-1.

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs.

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of Multiple Myeloma.

CNTO328 Abrogates Glucocorticoid (GC) Resistance Conferred by Interleukin (IL)-6 and the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Identification of Novel Inhibitors That Specifically Target the Immunoproteasome, and Selectively Induce Apoptosis in Multiple Myeloma and Other Immunoproteasome-Expressing Model Systems.

Inhibition of Interleukin-6 Signaling with CNTO328 Sensitizes Multiple Myeloma Cells to Bortezomib and Attenuates Proteasome Inhibitor-Mediated Induction of the Anti-Apoptotic Heat Shock Protein Response.

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only